Skip to main content
. 2019 Jun 2;1(7):303–311. doi: 10.1253/circrep.CR-19-0047

Table 3.

Medication at End of Study

  Group H
(n=87)
Group G
(n=42)
P-value
Oral PGI2 53 (61) 19 (45) 0.110
ERA 65 (75) 35 (83) 0.231
PDE-5I 52 (60) 28 (67) 0.449
Epo-iv 16 (18) 3 (7) 0.109
Anticoagulant 27 (31) 15 (36) 0.595
Diuretic 48 (55) 31 (74) 0.065
Digitalis 18 (21) 15 (36) 0.960
Monotherapy 36 (41) 8 (19) 0.012
Combination therapy 45 (52) 32 (76) 0.007

Data given as n (%). Abbreviations as in Table 1.